Transplantation, AutologousHematopoietic Stem Cell TransplantationTransplantation, HomologousTransplantation ConditioningLiver TransplantationBone Marrow TransplantationGraft vs Host DiseaseStem Cell TransplantationHematologic NeoplasmsKidney TransplantationMyeloablative AgonistsPeripheral Blood Stem Cell TransplantationGraft SurvivalWhole-Body IrradiationTreatment OutcomeTissue DonorsTransplantation ChimeraHeart TransplantationCell TransplantationUnrelated DonorsHistocompatibility TestingLung TransplantationMultiple MyelomaRecurrenceRetrospective StudiesCord Blood Stem Cell TransplantationHematopoietic Stem CellsImmunosuppressive AgentsGraft RejectionHistocompatibilityBusulfanCombined Modality TherapySurvival AnalysisRemission InductionGraft vs Tumor EffectTransplantation ImmunologyTransplantationOrgan TransplantationDisease-Free SurvivalSurvival RateMelphalanHematopoietic Stem Cell MobilizationTime FactorsLymphoma, Non-HodgkinLeukemiaVidarabineLeukemia, Myeloid, AcuteIslets of Langerhans TransplantationCyclophosphamidePancreas TransplantationSalvage TherapyAntigens, CD34Follow-Up StudiesHLA AntigensLiving DonorsSiblingsAntineoplastic Combined Chemotherapy ProtocolsDonor SelectionMyelodysplastic SyndromesChimerismGraft vs Leukemia EffectImmunosuppressionHematopoiesisTransplantation, IsogeneicHodgkin DiseaseCyclosporineBlood Transfusion, AutologousBone Marrow PurgingCarmustineGranulocyte Colony-Stimulating FactorBone Marrow CellsHematologic DiseasesMesenchymal Stem Cell TransplantationAcute DiseaseMycophenolic AcidPrognosisT-LymphocytesTransplantation, HeterotopicLeukapheresisPrecursor Cell Lymphoblastic Leukemia-LymphomaAntilymphocyte SerumDirected Tissue DonationHeart-Lung TransplantationEtoposideTransplantation ToleranceRisk FactorsPostoperative ComplicationsTacrolimusLymphocyte TransfusionAnemia, AplasticBone MarrowLymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytarabineTissue and Organ ProcurementSurvivorsCytomegalovirus InfectionsProspective StudiesFetal Tissue TransplantationNeoplasm, Residual